<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>REV-ERB agonist &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/rev-erb-agonist/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Jan 2026 11:52:36 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>REV-ERB agonist &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>REV-ERB Agonist Boosts Sorafenib Against Liver Cancer</title>
		<link>https://bioengineer.org/rev-erb-agonist-boosts-sorafenib-against-liver-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 11:52:11 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Drug synergy]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **karaciğer kanseri]]></category>
		<category><![CDATA[kombinasyon tedavisi** **Açıklama:** 1. **karaciğer kanseri:** Makalenin ana konusu ve araştırmanın odak noktasıdır. 2. **sorafenib:** Hepatosellüler karsinomda standart ted]]></category>
		<category><![CDATA[Liver Cancer Therapy]]></category>
		<category><![CDATA[Metabolic targeting]]></category>
		<category><![CDATA[metabolik hedefleme]]></category>
		<category><![CDATA[REV-ERB agonist]]></category>
		<category><![CDATA[Sorafenib]]></category>
		<category><![CDATA[SR9009]]></category>
		<guid isPermaLink="false">https://bioengineer.org/rev-erb-agonist-boosts-sorafenib-against-liver-cancer/</guid>

					<description><![CDATA[In a groundbreaking advance in liver cancer treatment, researchers have identified the metabolic clock protein REV-ERB as a pivotal factor in enhancing the efficacy of sorafenib, a frontline drug used against hepatocellular carcinoma. The study, led by Sabbioni, Guerriero, Shankaraiah, and colleagues, uncovers how the REV-ERB agonist SR9009 can potentiate sorafenib’s antitumor activity by exploiting [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318289</post-id>	</item>
	</channel>
</rss>
